Proprietary Protein Platform
IPLEX™ is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug, approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency, is currently being investigated in Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease, and Retinopathy of Prematurity (ROP).
